A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Public ClinicalTrials.gov record NCT06428409. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
Study identification
- NCT ID
- NCT06428409
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 220 participants
Conditions and interventions
Interventions
- Sacituzumab tirumotecan Biological
- Fluorouracil (5-FU) Drug
- Leucovorin (LV) or levoleucovorin Drug
- Rescue medication Drug
- Supportive care measures Drug
- Cisplatin Drug
- Pembrolizumab Biological
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 19, 2024
- Primary completion
- Oct 15, 2029
- Completion
- Oct 15, 2029
- Last update posted
- Sep 2, 2026
2024 – 2029
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA ( Site 0317) | Los Angeles | California | 90095 | Recruiting |
| University of Colorado Anschutz Medical Campus ( Site 0299) | Aurora | Colorado | 80045 | Recruiting |
| University of Colorado Anschutz Medical Campus ( Site 0325) | Aurora | Colorado | 80045 | Recruiting |
| University of Colorado Anschutz Medical Campus ( Site 0326) | Aurora | Colorado | 80045 | Recruiting |
| Sibley Memorial Hospital ( Site 0310) | Washington D.C. | District of Columbia | 20016 | Recruiting |
| University of Florida College of Medicine ( Site 0281) | Gainesville | Florida | 32610 | Recruiting |
| Mount Sinai Cancer Center ( Site 0287) | Miami Beach | Florida | 33140 | Recruiting |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0303) | Marietta | Georgia | 30060 | Completed |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0327) | Mineola | New York | 11501 | Recruiting |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324) | New York | New York | 10016 | Recruiting |
| University of Texas MD Anderson Cancer Center ( Site 0316) | Houston | Texas | 77030 | Recruiting |
| Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295) | Roanoke | Virginia | 24014 | Recruiting |
| University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293) | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06428409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 2, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06428409 live on ClinicalTrials.gov.